Study of tenofovir vaginal gel shows daily dosing ineffective due to lack of adherence

Previous study suggests coital dosing may be preferable and effective

2013-03-04

(Press-News.org) ARLINGTON, VIRGINIA (12:15 EST MARCH 4, 2013) — Researchers with the Microbicide Trials Network (MTN) today announced results of the Vaginal and Oral Interventions to Control the Epidemic (VOICE) study at the Conference for Retroviruses and Opportunistic Infections (CROI) in Atlanta, Georgia. The VOICE study tested oral and vaginal antiretroviral-based approaches as HIV prevention methods in 5,029 women in South Africa, Uganda, and Zimbabwe. Funded by the U.S. National Institutes of Health and managed by the MTN, the VOICE study was a major undertaking, which has provided important data regarding drug safety, effectiveness, acceptability and adherence.

"The principal investigators of the study, Drs. Jeanne Marazzo and Zvavahera Mike Chirenje, and the entire VOICE team have done an outstanding job," said CONRAD Executive Director Gustavo Doncel, M.D., Ph.D.

VOICE launched in September 2009 as a Phase IIB safety and effectiveness study to compare 3 different once-daily HIV prevention strategies: 1) a pill of combination emtricitabine and tenofovir (Truvada®), 2) a pill containing only tenofovir (Viread®), and 3) tenofovir 1% vaginal gel. Study participants received ongoing HIV risk-reduction counseling, condoms, and diagnosis and treatment of sexually transmitted infections throughout the trial. They were tested monthly for HIV and quarterly for drug levels.

In an evaluation of plasma samples in a subset of the women, drug was detected on average in 28% of participants taking oral tenofovir, 29% of participants taking oral Truvada, and 23% of participants in the vaginal gel study arm. Unfortunately, due to the low adherence, none of the products were deemed effective in reducing HIV acquisition in this particular trial. The estimates of effectiveness for both oral tenofovir and Truvada were less than zero. The study showed a 14.7% reduction of HIV infection in the tenofovir gel arm, when compared to placebo gel. This level of protection, however, was not statistically significant.

Some of the previous studies using the same antiretrovirals in tablet or gel form for HIV prevention showed effectiveness. In particular, CAPRISA 004, a study completed in 2010 using the same tenofovir vaginal gel used in the VOICE trial, showed an average of a 39% reduction in HIV infections and a 54% reduction in women who used it at least 80% of the time. Additionally, tenofovir gel reduced the risk of herpes genital infections by 51%. The dosing regimen was different than the daily dosing used in the VOICE study – women in CAPRISA 004 were required to insert 1 dose before sex and 1 dose after sex, not to exceed 2 doses in 24 hours (a regimen dubbed BAT24). CAPRISA 004 was the first trial to show that a topical product containing tenofovir could reduce HIV infection and suggests that a dosing method that requires women to use the product around the time of sex, versus daily dosing, may be preferable to women.

To that end, FACTS 001, a study sponsored by CONRAD, funded by USAID, the Bill & Melinda Gates Foundation and the South African government, and co-chaired by the South African scientists, Drs. Helen Rees and Glenda Gray, is currently being conducted at 9 sites in South Africa. The trial replicates the dosing regimen used in CAPRISA 004 (i.e., BAT 24). FACTS 001 is using a variety of methods to collect information about gel use, condom use, and sexual behavior in order to measure adherence. The study has enrolled close to 1,900 participants and is expected to be complete at the end of 2014. FACTS 001 is an important study as it is designed to confirm the results obtained in CAPRISA 004 and contribute to the approval of tenofovir gel as a pericoital method for prevention of HIV infection in women.

The VOICE study also found that single women under 25 were the least likely to use the product and the most likely to acquire HIV. "The VOICE results highlight the gravity of the epidemic, especially in young, unmarried women, and the importance of developing products that appeal to them. At CONRAD, we remain committed to designing HIV prevention products based on innovation and sound product development strategies," said Dr. Doncel.

"The results of the CAPRISA 004 and VOICE trials illustrate that there are some women who may only want to use a product when they know they are having sex and the FACTS 001 study plays a very important role in testing that hypothesis. We need more information on the type of products that women who are at the highest risk level want and will use," said Dr. Jill Schwartz, CONRAD's Medical Director.

### CONRAD, who has a royalty-free license to tenofovir gel from Gilead Sciences, manufactured and supplied the gel for these trials. CONRAD also holds the public sector licensing rights in developing countries for the prevention of genital herpes, a common sexually transmitted infection, through the use of tenofovir gel.

CONRAD was established in 1986 and is a Division of the Department of Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS) in Norfolk, VA, where it has laboratories and a clinical research center. Thanks to our funders, which include the U.S. Agency for International Development and the Bill and Melinda Gates Foundation, CONRAD is a leader in researching and developing new contraceptive options and products to prevent HIV and STIs. The main office is located in Arlington, VA and we collaborate with academic and research institutions around the world.

ELSE PRESS RELEASES FROM THIS DATE:

March story tips

2013-03-04

ENERGY – Reducing biorefinery waste . . . By introducing microbial fuel cells into the corn stover biorefinery waste recovery process, a team of researchers at Oak Ridge National Laboratory has demonstrated a new way to produce bioenergy from the process waste stream. The process developed by ORNL's Abhijeet Borole and colleagues from the University of Tennessee and National Renewable Energy Laboratory provides a direct alternative to generate electricity compared to a mature but multi-step path that uses anaerobic digestion. Major advantages of the ORNL method include ...

Toddler 'functionally cured' of HIV infection, NIH-supported investigators report

2013-03-04

A two-year-old child born with HIV infection and treated with antiretroviral drugs beginning in the first days of life no longer has detectable levels of virus using conventional testing despite not taking HIV medication for 10 months, according to findings presented today at the Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. This is the first well-documented case of an HIV-infected child who appears to have been functionally cured of HIV infection—that is, without detectable levels of virus and no signs of disease in the absence of antiretroviral ...

A billion deaths from tobacco are a key obstacle to global development

2013-03-04

If the word's nations are going to prevent tobacco smoking from causing one projected billion deaths by the end of this century, they must: Make tobacco control part of the agendas of United Nation's and other development agencies worldwide; Assure every sector of a nation including health, trade and finance officials work collectively to protect not only health but the harm tobacco places on their economy by passing laws to reduce use; Place health as the centerpiece of any decision on a trade treaty that includes tobacco; Diligently work toward a goal of reducing ...

Was King Richard III a control freak?

2013-03-04

University of Leicester psychologists have made an analysis of Richard III's character – aiming to get to the man behind the bones. Professor Mark Lansdale, Head of the University's School of Psychology, and forensic psychologist Dr Julian Boon have put together a psychological analysis of Richard III based on the consensus among historians relating to Richard's experiences and actions. They found that, while there was no evidence for Shakespeare's depiction of Richard III as a psychopath, he may have had "intolerance to uncertainty syndrome" – which may have manifested ...

International aid and advocacy groups are influenced by their home countries' cultures

2013-03-04

In February, Greenpeace activist and actress Lucy Lawless, star of "Xena: Warrior Princess," was sentenced to 120 hours of community service for boarding a Shell oil rig to protest offshore Arctic drilling. Dramatic protests by Netherlands-based Greenpeace contrast sharply with the lobbying and letter-writing of the U.S.-based Sierra Club. The differences among those two groups and other international non-governmental organizations (INGOs) reflect the cultures of the nations where they are based, according to research by a University of Missouri political scientist. Individuals ...

Vortex loops could untie knotty physics problems

2013-03-04

University of Chicago physicists have succeeding in creating a vortex knot—a feat akin to tying a smoke ring into a knot. Linked and knotted vortex loops have existed in theory for more than a century, but creating them in the laboratory had previously eluded scientists. Vortex knots should, in principle, be persistent, stable phenomena. "The unexpected thing is that they're not," said Dustin Kleckner, a postdoctoral scientist at UChicago's James Franck Institute. "They seem to break up in a particular way. They stretch themselves, which is a weird behavior." This behavior ...

Solutions Real Estate's Massive Success and Continued Growth is the Hottest Topic in San Diego Real Estate News Today

2013-03-04

Matt Johnson fell in love with San Diego in 1998, and has resided here ever since. He is familiar with the local neighborhoods inside and out, and has the ability to assist you in selecting the best one for your family's needs. Matt got his start in real estate at the age of 9, helping his Dad turn dilapidated old houses into the gem of the neighborhood. He later continued on that tradition, becoming a professional home renovator with operations in two states. Several years later, he realized his passion was in the sales and marketing side, so he obtained his license ...

Researchers discover how to shutdown cancer's powerful master protein

2013-03-04

NEW YORK (March 3, 2013) -- The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex to target with a drug since it is also crucial to the healthy functioning of many immune cells in the body, not just B cells gone bad. But now, in the journal Nature Immunology, researchers at Weill Cornell Medical College report that it is possible to shut down Bcl6 in the cancer, known as diffuse large B-cell lymphoma ...

7 genetic risk factors found to be associated with common eye disorder

2013-03-04

An international group of researchers has discovered seven new regions of the human genome—called loci—that are associated with increased risk of age-related macular degeneration (AMD), a leading cause of blindness. The AMD Gene Consortium, a network of international investigators representing 18 research groups, also confirmed 12 loci identified in previous studies. The findings are reported online today in the journal Nature Genetics. Supported by the National Eye Institute (NEI), a part of the National Institutes of Health, the study represents the most comprehensive ...

Scientists identify 'clean-up' snafu that kills brain cells in Parkinson's disease

2013-03-04

March 3, 2013— (Bronx, NY) — Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells. The study, which published online today in the journal Nature Neuroscience, could also open up treatment possibilities for both familial Parkinson's and the more common form of Parkinson's that is not inherited. Parkinson's disease is a gradually progressing disorder of the nervous system that causes stiffness or slowing of movement. According to the Parkinson's ...

LAST 30 PRESS RELEASES:

To improve screenings with technology, focus on people first

Implementing a digital cognitive screening tool and flexible workflow helps primary care clinics integrate dementia screening

American Heart Association stands together with Arkansas and against the soda industry to reduce sugary drink consumption

[Press-News.org] Study of tenofovir vaginal gel shows daily dosing ineffective due to lack of adherence
Previous study suggests coital dosing may be preferable and effective